key: cord-1052490-9jbzpodi authors: Khan, Abdul Arif; Khan, Zakir title: System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation date: 2020-10-22 journal: Chem Biol Interact DOI: 10.1016/j.cbi.2020.109299 sha: 0228841b8074f18dfd630fdcf341ad24cabfb371 doc_id: 1052490 cord_uid: 9jbzpodi COVID-2019 pandemic is affecting people worldwide in the absence of an effective treatment strategy. Several suggestive therapeutic options through drug repurposing are recommended, but a complete consensus is not reached. A combination of Hydroxychloroquine (HCQ) and Azithromycin (AZM) has been widely tried and discussed but its administration has also led to potential adversities in patients. Studies are suggesting that most prominent adverse event with HCQ and AZM combination is QT interval prolongation. We studied interaction of HCQ with AZM and subsequent effect of this drug combination on QT interval prolongation. We performed system biological investigation of HCQ and AZM targets and screened important targets and pathways possibly involved in QT interval prolongation. The best core hub protein drug targets involved in QT interval prolongation were identified as HSP90AA1 exclusively associated with HCQ, while AKT1 exclusively associated with AZM. It was found that PI3K/Akt, VEGF, ERBB2 pathways must be given consideration for understanding the role of HCQ and AZM in QT interval prolongation. Conclusion: Computational methods have certain limitations based on source database coverage and prediction algorithms and therefore this data needs experimental correlation to draw final conclusion, but current findings screen targets for QT interval prolongation associated with HCQ and AZM. These proteins and pathways may provide ways to reduce this major risk associated with this combination. Recent COVID-19 pandemic raised several challenges in front of scientific community in the 42 absence of widely accepted therapeutic intervention. The use of Hydroxychloroquine (HCQ) was 43 also debated globally during this pandemic with wide range of observations, making it difficult 44 to reach complete consensus about potential of this drug as therapeutic intervention for COVID 45 [1] . It was suggested that use of HCQ has potential to manage COVID-19 [2, 3] and 46 azithromycin (AZM) enforce this ability [4] .In contrast, the use of this combination may cause several adverse events, including QT interval prolongation, hypoglycemia, and neuropsychiatric In this article, we performed network pharmacology analyses of HCQ and AZM targets to 58 understand the mechanisms of adverse events associated with this drug combination. We 59 analyzed targets of these two drugs and their involvement in QT interval prolongation. We also 60 identified targets linked with HCQ and/or AZM and involved in QT interval prolongation in 61 addition to metabolic pathways modulated by these target proteins. Consequently, we present 62 J o u r n a l P r e -p r o o f here a bioinformatics analyses of HCQ and AZM targets for understanding effect of these drugs 63 alone and in combination for QT interval prolongation. Table S4 128 gives detail about targets obtained from both databases. During analysis of QT interval prolongation targets affected by HCQ and AZM, we found 132 common targets between HCQ, AZM and QT interval prolongation. Table 1 gives detail about 133 target proteins involved in QT interval prolongation that could be affected by HCQ and/or AZM. Total 73/1073 QT interval prolongation targets were found to get affected by HCQ and/or AZM. (Table S6 and S7). It will be interesting to verify these common targets in Table S6 ). Whereas, AZM was found to interact with 220 more hub proteins (Figure 4 ) and support that HCQ may be directly involved in targeting 221 mediators of cardiac arrhythmia, but AZM integrates more hub proteins in the process, and 222 therefore it can intensify the chances of QT interval prolongation. These results are consistent 223 with the finding obtained through clinical studies. During enrichment analysis of metabolic pathway modulation during single or co-administration 225 of HCQ and/or AZM, we found that these two drugs can modulate several metabolic and other 226 pathways associated with cardiac arrhythmia. It has been implicated that drug mediated long QT 227 syndrome is associated with inhibition of PI3K/Akt signaling [25] . We found that HCQ and Although, all these studies present promising targets and pathways for their involvement in QT 252 interval prolongation, but this work is based on existing information obtained from widely 253 known databases. All the databases are continuously evolving and their coverage of certain 254 information is not complete, in addition computational prediction algorithms are also having 255 several limitations. Therefore we must consider limitations of computational predictions and 256 these findings must be correlated with experimental evidences in order to draw final conclusion. In spite of that, this study shortlists several potential targets and mechanisms which can be useful 258 to find management strategies for HCQ and AZM associated adverse events. Under current 259 scenario, this study holds its value as this combination is widely discussed throughout the globe 260 and attracted scientific community. Are hydroxychloroquine and chloroquine effective in the 283 treatment of SARS-COV-2 (COVID-19)?, Evidence-based dentistry Efficacy of chloroquine and hydroxychloroquine in the treatment 285 of COVID-19 Healthcare workers & SARS-CoV-2 infection in India: A 288 case-control investigation in the time of COVID-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an 293 open-label non-randomized clinical trial Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the 295 management of SARS-CoV-2 infection Cardiovascular risks of hydroxychloroquine in treatment and 299 prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society, Indian 300 pacing and electrophysiology journal Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy Treatment options for COVID-19: The reality and challenges Anti-colorectal cancer targets of 307 resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and 308 experimental data SuperPred: update on drug classification and target prediction SwissTargetPrediction: updated data and new features for efficient 316 prediction of protein targets of small molecules The DisGeNET knowledge platform for disease genomics: 2019 update The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence 323 Network analysis, and human and animal studies disclose 325 the anticystitis glandularis effects of vitamin C GOlorize: a Cytoscape plug-in for network visualization with Gene Ontology-based layout and coloring BiNGO: a Cytoscape plugin to assess overrepresentation of gene 330 ontology categories in biological networks The reactome pathway 334 knowledgebase Risk of 336 QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant 337 Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease Experience With Hydroxychloroquine and Azithromycin in the Pandemic: Implications for QT Interval Monitoring Anticancer targets and mechanisms of calycosin to 348 treat nasopharyngeal carcinoma Bioinformatic and biochemical findings 350 disclosed anti-hepatic steatosis mechanism of calycosin Therapeutic target and molecular mechanism of 352 vitamin C-treated pneumonia: a systematic study of network pharmacology Control of cardiac repolarization by phosphoinositide 3-kinase 355 signaling to ion channels Unified nexus of macrophages and maresins in cardiac reparative 357 mechanisms, FASEB journal : official publication of the Federation of American Societies for 358 Management of QT 360 prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for 361 different drugs QTc interval prolongation with 363 vascular endothelial growth factor receptor tyrosine kinase inhibitors COVID-19: risk for cytokine targeting in chronic 366 inflammatory diseases? Controversies about COVID-19 and anticancer treatment with immune checkpoint 368 inhibitors